Servier Pays $210M Upfront for Ex-US Rights to Ideaya’s PKC Inhibitor Darovasertib

Servier is paying $210 million upfront to license regulatory and commercial rights to Ideaya Biosciences’ experimental PKC inhibitor, darovasertib, outside the US1 2 3 5.

Ideaya retains US rights to darovasertib and will receive up to $100 million in regulatory milestones and up to $220 million in commercial milestone payments from Servier, for a total deal value that could reach $530 million1 2 3 4 5.

Darovasertib is a potential first-in-class, potent and selective PKC inhibitor being developed for the treatment of uveal melanoma (UM), a rare and aggressive form of eye cancer with high unmet need1 2 3 4.

The companies will collaborate on development and share related costs. Darovasertib is currently in multiple Phase 2/3 clinical trials for both primary and metastatic uveal melanoma, including studies in combination with Pfizer’s Xalkori (crizotinib) and as a neoadjuvant monotherapy1 2 3 4.

Ideaya is also eligible for double-digit royalties on sales of darovasertib outside the US1 2 3 5.

Regulatory highlights include FDA Breakthrough Therapy and Fast Track designations for darovasertib in uveal melanoma4.

Sources:

1. https://www.fiercebiotech.com/biotech/servier-shells-out-210m-upfront-license-ideayas-potential-first-class-pkc-inhibitor-outside

2. https://www.prnewswire.com/news-releases/servier-and-ideaya-biosciences-partner-to-bring-darovasertib-a-promising-uveal-melanoma-treatment-to-patients-worldwide-302543276.html

3. https://www.biospace.com/business/servier-commits-up-to-530m-into-eye-cancer-deal-with-ideaya

4. https://trial.medpath.com/news/b3a4c4eb1f304ace/servier-and-ideaya-biosciences-strike-530m-partnership-for-uveal-melanoma-drug-darovasertib

5. https://www.oncologypipeline.com/apexonco/servier-eyes-ideayas-darovasertib

Sources:

Leave a Reply Cancel reply